The European Society for Medical Oncology’s annual meeting this week featured the hottest emergent areas of cancer ...

Merck and Daiichi Sankyo's HER3 antibody-drug conjugate reported a positive phase 3 result in EGFR-mutated lung cancer. Merck ...

It was a busy week for the biotech sector with a lot of important data readouts at the European Society for Medical Oncology ...

Alongside Summit, there are quite a few other players in the field. Some if these companies have even already shown promising ...

Discover they major updates in oncology from the 2024 ESMO Congress, including featured breakthroughs from the leading ...

Cachexia is a wasting syndrome prevalent in cancer patients (as well as patients with other conditions) that is marked by weight loss, loss of muscle mass, fatigue, and lack of appetite, and is ...

Shares of Nuvalent NUVL have soared nearly 20% in the past week owing to encouraging updates on its two investigational ...

Researchers analyzed molecular and particulate matter exposure data on nearly 9,000 NSCLC patients in France and confirmed a link reported by UK scientists in 2022.

Summit Therapeutics’ ivonescimab has the potential to challenge Merck’s blockbuster checkpoint inhibitor in non-small cell ...

Innovent Biologics has made the case that its checkpoint inhibitor-cytokine fusion protein has a future in colorectal cancer.

The recent ESMO 2024 data highlighted significant advancements in immunotherapy. Check out the results from Merck, BMY, ...

Amivantamab plus chemotherapy delivered promising OS trends compared with chemotherapy in EGFR-mutant advanced non-small cell ...